

Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: www.ajicjournal.org



Major Article

Multicenter study in Colombia: Impact of a multidimensional International Nosocomial Infection Control Consortium (INICC) approach on central line–associated bloodstream infection rates



Carlos A. Álvarez-Moreno MD^a, Sandra L. Valderrama-Beltrán MD^b, Víctor D. Rosenthal MD^{c,*}, Beatriz E. Mojica-Carreño MD^d, Ismael A. Valderrama-Márquez MD^e, Lorena Matta-Cortés^f, Sandra M. Gualtero-Trujillo^b, Jazmín Rodríguez-Peña^b, Claudia J. Linares-Miranda MD^b, Ángela P. Gonzalez-Rubio MD^b, María C. Vega-Galvis MD^b, Iván Riaño-Forero MD^b, Beatriz E. Ariza-Ayala MD^b, Germán García-Laverde MD^d, Otto Susmann MD^d, Oscar Mancera-Páez MD^e, Narda Olarte^e, Luis F. Rendón-Campo^f, Yamileth Astudillo^f, María del Socorro Trullo-Escobar MD^f, Pablo W. Orellano DrPH^{c,g}

^a Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia

^b Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia

^c International Nosocomial Infection Control Consortium, Buenos Aires, Argentina

^d Clínica Nueva, Bogotá, Colombia

^e Hospital El Tunal ESE, Bogotá, Colombia

^f Corporación Comfenalco Valle, Universidad Libre, Santiago de Cali, Colombia

g Universidad Tecnológica Nacional, Facultad Regional San Nicolás and Consejo Nacional de Investigaciones Científicas y Técnicas, San Nicolás, Argentina

Key Words: Hospital infection health care–acquired infection device-associated infection developing countries limited-resource countries low-income countries critical care surveillance incidence density bundle **Background:** The objective of this study was to analyze the impact of a multidimensional infection control approach and the use of the International Nosocomial Infection Control Consortium (INICC) Surveillance Online System on central line–associated bloodstream infection (CLABSI) rates from June 2003-April 2010. *Methods:* We conducted a prospective, before-after surveillance study of 2,564 patients hospitalized in 4 adult intensive care units (ICUs) and 424 patients in 2 pediatric ICUs of 4 hospitals in 2 cities of Colombia. During baseline, we performed outcome surveillance of CLABSI applying the Centers for Disease Control and Prevention's National Healthcare Safety Network definitions. During intervention, we implemented the INICC multidimensional approach and the ISOS, which included a bundle of infection prevention practice interventions, education, outcome surveillance. Bivariate and multivariate regression analyses were performed using a logistic regression model to estimate the effect of the intervention on the CLABSI rate. *Results:* The baseline rate of 12.9 CLABSIs per 1,000 central line (CL) days, with 3,032 CL days and 39 CLABSIs, was reduced to 3.5 CLABSIs per 1,000 CL days, with 3,686 CL days and 13 CLABSIs, accounting for a 73% CLABSI rate reduction (relative risk, 0.27; 95% confidence interval, 0.14-0.52; *P=*.002).

Conclusions: Implementing the INICC multidimensional infection control approach for CLABSI prevention was associated with a significant reduction in the CLABSI rate of ICUs of Colombia.

© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

* Address Correspondence to Victor D. Rosenthal, MD, International Nosocomial Infection Control Consortium, 11 de Septiembre 4567, Floor 12th, Apt 1201, Buenos Aires 1429, Argentina.

E-mail address: victor_rosenthal@inicc.org (V.D. Rosenthal).

Funding/Support: The funding for the activities carried out at the International Nosocomial Infection Control Consortium Headquarters was provided by the corresponding author, Victor D. Rosenthal, and the Foundation to Fight against Nosocomial Infections.

Conflicts of Interest: None to report.

Author Contributions: All authors were involved in study conception and design, drafting of the manuscript, provision of study patients, collection of data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript. V.D.R. was responsible for software development; data assembly, analysis, and interpretation; epidemiologic analysis; statistical analysis; and technical support.

Additional Information: Every hospital's institutional review board agreed to the study protocol, and patient confidentiality was protected by codifying the recorded information, making it only identifiable to the infection control team.

0196-6553/© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. http://dx.doi.org/10.1016/j.ajic.2016.03.043

Central line-associated bloodstream infection (CLABSI) is considered to be among the most serious device-associated infections in the intensive care unit (ICU) setting.^{1,2} According to studies from developed² and limited-resource countries,^{3,4} the most important clinical consequences attributable to CLABSI are increased mortality rates, significant morbidity, and increased length of stay (LOS). From an economic perspective, CLABSIs are also responsible for significant increases in health care costs, as reported in both developed^{2,5} and limited-resource countries.^{3,4} The burden posed by CLABSI has not been systematically analyzed in limited-resource countries.⁶ Although hospitals in limited-resource countries do implement basic infection control programs, compliance with infection control practices is variable.⁶ As reported by the International Nosocomial Infection Control Consortium (INICC) in pooled studies⁷⁻¹¹ and in particular studies from Colombia,¹² the rates of CLABSI have been determined to be from 3-5 times higher than in Western countries.

It has been shown that the incidence of CLABSI in Western countries can be substantially prevented and reduced by >30% through basic but effective measures,¹³ such as those described in the bundle for CLABSI prevention developed by the Institute for Healthcare Improvement¹⁴: (1) hand hygiene, (2) skin antisepsis with chlorhexidine, (3) maximal barriers, (4) insertion in subclavian vein, and (5) timely central line (CL) removal—were associated with a reduction in the incidence density of CLABI in developed countries.¹⁵

The present study was designed to determine the effect of the INICC multidimensional program for reduction of CLABSI rates in 4 adult ICUs and 2 pediatric ICUs of 4 hospitals of 2 cities in Colombia. Our program was implemented from June 1, 2003-April 30, 2010, and included 6 simultaneous interventions: (1) bundle of infection prevention practices, (2) education, (3) outcome surveillance, (4) feedback of CLABSI rates and adverse consequences, (5) feedback on CLABSI rates and consequences, and (6) performance feedback of process surveillance.

Outcome surveillance is conducted by means of an online platform called the INICC Surveillance Online System (ISOS), which is comprised of 15 modules whose effective impact in CLABSI rates reduction was shown in several studies.¹⁶⁻²³ The ISOS allows the classification of prospective, active, cohort surveillance data into specific module protocols that apply the U.S. Centers for Disease Control and Prevention's (CDC's) National Healthcare Safety Network (NHSN) definitions.²⁴

The bundles of infection prevention practices of the INICC Multidimensional Approach (IMA) follow the basic recommendations published in the guidelines of the Society for Healthcare Epidemiology of America and Infectious Diseases Society of America in 2008²⁵ and the CDC in 2002.²⁶ At present, there is sufficient ethical and theoretical justification for conducting this particular study, and through its publication we can increase and spread awareness on this public health burden in Colombia.

METHODS

Background on the INICC

Founded in Argentina in 1998, the INICC was the first multinational research network established to control and reduce health care–associated infections (HAIs) at the international level through the analysis of data collected on a voluntary basis by a pool of hospitals worldwide.¹¹ The goals of the INICC include the development of a dynamic global hospital network that applies systematic surveillance of HAIs with standardized definitions and methodologies of the CDC-NHSN,²⁴ promotes evidence-based infection control practices, and performs applied infection control research to reduce rates of HAI, associated mortality, excess LOSs, costs, and bacterial resistance.²⁷

Setting and study design

This multicenter, prospective, before-after study was conducted in 4 adult ICUs (3 medical-surgical and 1 coronary ICUs) and 2 pediatric ICUs of 4 INICC member hospitals in 2 cities from Colombia. This hospital had been actively implementing the IMA, as subsequently described, during a 3-month period for the baseline period and the following months for the intervention period, with an infection control team (ICT) comprised of infection control professionals and medical doctors with formal education and background in internal medicine, critical care, infectious diseases, microbiology, and hospital epidemiology.

Baseline period

The baseline period included only the performance of outcome surveillance and process surveillance. The length of the baseline period is 3 months for the following reasons. First, the sample size of patients and the number of months of data collection during the baseline period are sufficient enough to compare with the sample size of patients and the number of months of data collection during the intervention period. From a statistical perspective, the issue is addressed by considering the changes in rates over time. The relatively short baseline period may impact the SEM of our estimates. However, we found that this will not cause a bias in the results because there will not be systematic differences between the 2 groups. Second, our priority is to start the intervention as early as possible to achieve the desired results, such as lower CLABSI rates, as soon as possible.

Intervention period

The intervention period started in the fourth month of participation. This is a prospective cohort study, and each ICU joined the INICC program at different moments. Therefore, by the time we analyzed the impact of the INICC intervention, we had ICUs with different lengths of participation in the intervention period. For the coronary ICU, the baseline period was from September 1, 2003-November 30, 2003, and the intervention period was from December 1, 2003-June 30, 2004. For the 2 pediatric ICUs, one had a baseline period from September 1, 2003-November 30, 2003, and an intervention period from December 1, 2003-July 31, 2005, and the other had a baseline period from October 1, 2009-December 31, 2009, and an intervention period from January 1, 2010-April 30, 2010. The 3 medical-surgical ICUs also had different periods of participation: a baseline period from June 1, 2003-August 31, 2003, and an intervention period from September 1, 2003-November 31, 2004; a baseline period from April 1, 2003-June 30, 2003, and an intervention period from July 1, 2003-July 31, 2004; and a baseline period from June 1, 2003-August 31, 2003, and an intervention period from September 1, 2003-December 31, 2004.

IMA

The IMA includes the implementation of the CDC-NSHN methodology, but it adds the collection of other data essential to increase infection control professional's sensitivity to detect HAIs and avoid underreporting.²⁴ According to standard CDC-NSHN methods, numerators are the number of HAIs of each type, and denominators are device days collected from all patients, as pooled data, without determining the number of device days related to a particular patient and without collecting characteristics per specific patient.²⁴ This design differs from the IMA because the design of the cohort study through the INICC methods also includes collecting specific data per patient from all patients, both those with and those without HAI, collecting risk factors of HAIs (eg, invasive devices), and collecting surrogates of HAIs, which include, but are not limited to, high temperature, low blood pressure, results of cultures, antibiotic therapy, LOS, and mortality. By collecting data on all patients in the ICU, it is possible to match patients with and without HAI by several characteristics to estimate extra LOS, mortality, and cost.

The IMA is comprised of the simultaneous implementation of the following 6 components for HAI control and prevention: (1) a bundle of infection prevention practices, (2) education, (3) outcome surveillance, (4) process surveillance, (5) feedback on HAI rates and consequences, and (6) performance feedback.

The ISOS is comprised of 15 modules, 10 for outcome surveillance and 5 for process surveillance. The modules of the outcome surveillance and process surveillance components may be used singly or simultaneously, but once selected, they must be used for a minimum of 1 calendar month.

Bundle of infection prevention practices

The bundles of infection prevention practices were designed following the recommendations and guidelines published by the CDC in 2002²⁶ and the Society for Health Care Epidemiology of America and the Infectious Diseases Society of America published in 2008.²⁵ These guidelines describe different recommendations for HAI prevention that are classified into categories regarding the existing scientific evidence, applicability, and prospective economic effects.

The components of the INICC infection control bundle for CLABSI prevention²⁵ are as follows: (1) perform hand hygiene before CL insertion or manipulation²⁸; (2) use sterile gauze or transparent sterile dressing to cover insertion site²⁵; (3) maintain good condition of sterile dressing, and change gauze every 48 hours and transparent dressing every 7 days²⁵; (4) remove CL as early as possible, when not necessary, to have lower device utilization ratio (DUR) and shorter length of device use²⁵; (5) change administration set every 96 hours, unless used for fat, nutrition, or blood precuts, and in these cases changed every 24 hours²⁵; (6) use a chlorhexidine-based antiseptic for skin preparation (implemented in 2006)²⁵; (7) preferably use subclavian vein²⁵; (8) use maximal sterile barrier precautions during CL insertion²⁵; (9) avoid multiple uses of vials meant to be used only once²⁵; (10) disinfect line hubs, needleless connectors, and infection ports before accessing the CL²⁵; and (11) use closed collapsible flexible containers instead of open semirigid vented or glass vented intravenous containers.²⁹

Education

Education to health care workers included information about infection control measures specific for CLABSI, based on the mentioned guidelines and recommendations, and the correct procedures and technique for hand hygiene.

Outcome surveillance

Prospective active outcome surveillance through the ISOS allows the classification of prospective, active, cohort surveillance data into specific module protocols that apply CDC-NHSN definitions published in 1991.²⁴ The site-specific criteria include reporting instructions and providing full explanations integral to their adequate application.²⁴

Process surveillance

The process surveillance is performed through the ISOS modules, which include the monitoring of compliance with some bundle elements for CLABSI prevention, including the (1) proportion of inserted CLs; (2) proportion of dressing placed to protect the puncture site; (3) proportion of dressings in correct condition and evaluating if the dressing was clean, dry, and correctly adhered to

the puncture site; (4) proportion of cases in which dates of insertion were written in the administration set of the patient or the dressing; (5) DUR; and (6) length of CL use.

Feedback on device-associated HAI rates and consequences

Health care workers receive feedback on device-associated HAI rates and their consequences at monthly meetings, by means of the review of reports generated through the ISOS,²⁷ which contains charts and tables with a running record of the monthly data of cohort surveillance. This infection control tool is important to increase awareness about outcomes of patients at their ICU, enable the ICT and ICU staff to focus on the necessary issues, and apply specific strategies for improvement of high device-associated HAI rates.

Performance feedback

This infection control tool is essential to enable the ICT and ICU staff to focus on the necessary strategies for improvement of low compliance rates.

Performance feedback is provided to health care workers working in the ICU by communicating the assessment of practices routinely performed by them. The resulting rates are reviewed by the ICT with ICU staff at monthly meetings, showing bar charts with compliance with infection control measures to prevent CLABSIS.^{28,30,31}

Data collection and analysis

The ISOS meets the criteria set forth in the INICC protocol, which is followed by the infection control professionals who collect daily data on CLABSIs, catheter-associated urinary tract infections, and ventilator-associated pneumonias and denominator data, patient days, and specific device days in the ICUs.

Definitions

We applied CDC-NHSN definitions for CLABSI published by the CDC-NSHN in $1991.^{24}$

Statistical methods

ISOS version 2.0 (INICC, Buenos Aires, Argentina) was used to calculate HAI rates and the DUR.

Patients' characteristics were compared using Fisher exact tests for dichotomous variables and unmatched Student *t* tests for continuous variables. *P* values <.05 by 2-sided tests were considered significant.

We conducted 2 types of analysis to evaluate the impact of our intervention on CLABSI rates. First, we performed an analysis to compare the data of the first 3 months (baseline period) with the remaining pooled months (intervention period) using relative risks, 95% confidence intervals (CIs), and P values. Second, to analyze progressive CLABSI rate reduction, we divided the data into the first 3 months (baseline period) followed by the 6-month follow-up periods (intervention period). We compared the CLABSI rates for each followup period with the baseline CLABSI rate. We calculated the incidence density rates (IDR), IDR ratios, and IDR reduction to account for the CLABSI rate reduction. Third, we estimated the effect of the intervention on the CLABSI by means of a logistic regression model. A set of covariables was included to account for possible interactions and confusion effects. A backward procedure that compares between nested models using the Akaike information criterion was carried out to get the final set of significant covariables. Collinearity among independent variables was measured using the variance inflation factor. We calculated the odds ratio (OR) and 95% CI for the intervention and other independent variables. The effectiveness of the intervention was calculated using the formula: $(1 - OR) \times 100$, where OR is the adjusted OR estimated by the model. All statistical analyses were performed using the R software version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

During the study period, we recorded a total of 2,988 patients, hospitalized for 17,370 days, with a total of 13,263 CL days, at 4 hospitals in the following 3 types of ICUs: pediatric (n = 424), coronary (n = 373), and medical-surgical (n = 2,191).

Patients' characteristics, such as sex and age, were similar during both periods.

Regarding the results of the measurement of the bundle components, we registered statistically significant improvements in hand hygiene compliance and lower CL DUR (Table 1).

The average length of CL use was lower during the intervention period (Table 1).

The levels of compliance with date on administration set, placed dressing, and correct condition of dressing were high at baseline and remained at the same level during the intervention period (Table 1).

During the baseline period, we recorded 3,032 CL days for a CL use mean of 5.6. There were 39 CLABSIs for an overall baseline rate of 12.9 CLABSIs per 1,000 CL days. (Table 2) Merging all data of the intervention period, during the implementation of the multidimensional infection control program, we recorded 10,231 CL days for a CL use mean of 4.2. The rate of CLABSIs per 1,000 CL days was reduced to 3.5 CLABSIs per 1,000 CL days in the second year, accounting for a 73% cumulative CLABSI rate reduction (IDR ratio, 0.27; 95% CI, 0.14-0.52; *P*=.001) (Table 2 and Fig 1).

The results of the logistic regression model are presented in Table 3. These results showed a significant reduction in the CLABSI

risk in patients during the intervention period, when controlling for the number of CL days and patients' ages (OR, 0.52; 95% CI, 0.33-0.81). The model also detected a significant excess risk for a unit increase in the CL days (OR, 1.10; 95% CI, 1.08-1.12). The adjusted effectiveness of the intervention was 48% (95% CI, 19%-67%). There was no significant interaction detected between the intervention and the number of CL days. Collinearity indices in the final model were low (1.001-1.003), indicating the absence of multicollinearity among the independent variables.

The microorganisms profile is shown in Table 4. The predominant microorganisms were *Staphylococcus aureus* and coagulasenegative *Staphylococcus* in both periods.

DISCUSSION

This study was conducted with the aim of assessing the effect of a multidimensional infection control approach in the ICU setting in Colombia. The comparison of the baseline rate of CLABSI found in this study (12.9 per 1,000 CL days) shows it is almost 10-fold higher than the United State's 0.8 CLABSI rate per 1,000 CL days determined by the CDC-NHSN for 2013³² and the 1.4 rate determined by the Krankenhaus Infektions Surveillance System (KISS), the German nosocomial infection surveillance system for ICUs.³³ In comparison with CLABSI rates from other developing countries, our CLABSI baseline rate was higher than the last international INICC report for 2007-2012 (4.9 CLABSIs per 1,000 CL days; 95% CI, 4.8-5.1).¹¹ Within the limited scope of studies addressing the burden of CLABSIs in Colombia, in a study conducted by Villalobos et al in 10 ICUs, it was shown that the CLABSI rate was 4.8 per 1,000 CL days.³⁴

In our study, the high CLABSI rate at baseline was reduced from 12.9 to 3.5 per 1,000 CL days (rate ratio, 0.27; 95% CI, 0.14-0.52; P=.001), showing a 73% CLABSI rate reduction. This reduction can

Table 1

Patient characteristics, device use, and central line-associated bloodstream infection rates and compliance with care bundle in the baseline and intervention periods

Patient characteristics	Baseline period	Intervention period	RR (95% CI)	P value
Study period by hospital in months, mean (range)	3	12.5 (6.0)	-	-
Patients, n	544	2,444	-	-
Bed days, n*	3,575	13,795	-	-
CL days, n [†]	3,032	10,231	-	-
Age, mean ± SD	44.2 ± 23.2	44.8 ± 24.6		.590
Male, n (%)	304 (55.9)	1,285 (52.6)	-	.772
Bundle to prevent CLABSI				
Hand hygiene compliance, % (n/n)	50 (351/703)	76 (558/732)	0.77 (0.70-0.86)	.001
Compliance with date on administration set, % (n/n)	91 (803/878)	87 (2,691/3,097)	1.02 (1.0-1.1)	.929
Compliance with placed dressing, % (n/n)	85 (744/878)	82 (2,531/3,097)	1.02 (0.9-1.1)	.520
Compliance with correct condition of dressing, % (n/n)	86 (753/878)	78 (2,429/3,097)	1.05 (1.0-1.1)	.110
Average length of CL use \pm SD	5.6 ± 10.9	4.2 ± 7.3	-	.001
CL utilization ratio (DUR) [‡]	0.85	0.74	-	.001

CI, confidence interval; CL, central line; CLABSI, central line-associated bloodstream infection; RR, relative risk.

*Bed days are the total number of days that patients are in the ICU during the selected time period.

[†]CL days are the total number of days of exposure to CLs by all of the patients in the selected population during the selected time period. [‡]DUR: CL days divided by the number of bed days.

Table 2

Central line-associated bloodstream infection rates stratified by length of participation of each intensive care unit

Months since joining INICC	No. of ICUs	CL days	CLABSI	Crude CLABSI rate/1,000 CL days (IDR)	IDR ratio (95% CI)	IDR reduction (%)	<i>P</i> value
1-3 mo (baseline)	6	3,032	39	12.9	-	-	-
4-12 mo	6	6,545	69	10.5	0.82 (0.55-1.2)	18	.323
Second year	4	3,686	13	3.5	0.27 (0.14-0.52)	73	.001

CI, confidence interval; *CL*, central line; *CLABSI*, central line–associated bloodstream infection; *ICU*, intensive care unit; *IDR*, incidence density rate; *INICC*, International Noso-comial Infection Control Consortium.



Fig 1. Central line-associated bloodstream infection rate reduction by length of participation of each intensive care unit.

Table 3

Results of the logistic regression model showing the effect of the INICC intervention on the central line-associated bloodstream infection rates

Variables	Coeff (SEM)	Adjusted OR* (95% CI)	P value
Period (intervention)	-0.658 (0.231)	0.52 (0.33-0.81)	<.001
CL days [†]	0.097 (0.009)	1.10 (1.08-1.12)	<.001
Age	-0.014 (0.005)	0.99 (0.98-1.00)	<.001

CI, confidence interval; *CL*, central line; *Coeff*; β coefficient of the logistic regression; *INICC*, International Nosocomial Infection Control Consortium; *OR*, odds ratio. *Adjusted OR for the logistic regression model including the 3 variables in the table. [†]CL days is the total number of days of exposure to the central line by all of the patients in the selected population during the selected time period.

Table 4

Microorganisms related to central line-associated bloodstream infection in intensive care units in the baseline and intervention periods

Isolated microorganisms	Baseline	Intervention
Acinetobacter spp	2(1)	16(18)
Coagulase-negative Staphylococcus	16(7)	21 (23)
Escherichia coli	2(1)	11(12)
Klebsiella pneumoniae	7(3)	7(8)
Pseudomonas spp	16(7)	3(3)
Staphylococcus aureus	42 (18)	30 (34)
Others*	14(6)	13(14)
Total	100 (43)	100(112)

NOTE. Values are % (n).

*Others refers to the following isolated microorganisms: Alcaligenes spp, Candida spp, Citrobacter spp, Enterobacter spp, Enterococcus spp, Haemophilus spp, Morganella spp, Proteus spp, Serratia spp, and Stenotrophomonas spp.

be associated with the implementation of the IMA, this approach enabled significant improvements in the compliance with most of the bundle components, such as more hand hygiene, less DUR, and reduced average length of CL. In addition, compliance with other measures, such as compliance with date on administration set, compliance with placed dressing, and compliance with correct condition of dressing, was high and similar in both phases. Furthermore, patients' characteristics, such as sex and age, were similar during both periods.

The logistic regression analysis showed that the intervention led to a significant reduction in the CLABSI risk, and this relationship was modulated by the number of CL days and the patient's age. Moreover, based on the model's results, the effectiveness of the intervention was nearly 50%, which means there was a significant reduction in the patients' CLABSI risk associated with the INICC method.

One reference from the literature showing a similar reduction was published by Osorio et al, who found that a program based on the implementation of a CLABSI prevention bundle reduced the incidence of CLABSI from 5.56 CLABSIs per 1,000 CL days to 3.26 per 1,000 CL days.³⁵ Similarly, it was shown in previous studies performed by the INICC that implementation of a 4- or 6-component multidimensional approach for CLABSI resulted in significant reductions in rates of CLABSI in Argentina (46.63 vs 11.10 CLABSIs per 1,000 CL days, showing a 76% reduction)¹⁹; in Mexico (46.3 vs 19.5 CLABSIs per 1,000 CL days, showing a 58% reduction)²⁰; in Turkey $(22.7 \text{ vs } 12.0 \text{ CLABSIs per } 1,000 \text{ CL days, showing a } 47\% \text{ reduction})^{22}$; in India (6.4 vs 3.9 CLABSIs per 1,000 CL days, showing a 39% reduction)²¹; in adult ICUs (14.5 vs 9.7 CLABSIs per 1,000 CL days, showing a 33% reduction)¹⁶; in pediatric ICUs (10.7 vs 5.2 CLABSIs per 1,000 CL days, showing a 51% reduction)¹⁷; and in neonatal ICUs (21.4 vs 9.7 CLABSIs per 1,000 CL days, showing a 55% reduction).18

Regarding the microorganisms profile, we identified a predominance of *S aureus* and coagulase-negative *Staphylococcus*. Olarte et al showed in a previous study in Colombia that *S aureus* is the most frequent microorganism isolated in ICU patients.³⁶ The increase in the number of isolated *Acinetobacter* spp during the intervention period may be associated with the presence of outbreaks in some of the participating institutions.

Study limitations

The main limitation of this study is that our findings cannot be generalized to all ICU patients from Colombia. However, in this study it was proved that a multidimensional approach is fundamental to fights against the incidence of CLABSIs in the ICU setting.

Second, the setting of a 3-month baseline period may be short and might have overestimated the effect of the intervention. Nevertheless, during the baseline period, the sample size was good enough, and the CIs for the baseline rate were narrow. Third, there may be significant variations in the level of quality control in the ICTs that support each individual hospital, and we could not quantify in detail all the interventions included in our multidimensional approach, such as education and compliance with hand hygiene practice.

CONCLUSIONS

This is the first study to report a substantial reduction in CLABSI rates in the ICU setting of Colombia. The implementation of our multidimensional approach resulted in significant reductions in the CLABSI IDR. These systematically collected data serve as guidance for strategies to improve patient care practices, as demonstrated in several studies conducted in limited-resource countries. These preventive strategies proven effective in the INICC ICUs of Colombia can promote a wider acceptance of infection control programs in hospitals, leading to significant CLABSI rate reduction worldwide.

Acknowledgments

We thank the many health care professionals at each member hospital who assisted with the conduct of surveillance in their hospital; Mariano Vilar and Débora López Burgardt, who work at INICC Headquarters in Buenos Aires; the INICC Country Directors and Secretaries (Haifaa Hassan Al-Mousa, Hail Alabdaley, Areej Alshehri, Altaf Ahmed, Carlos A. Álvarez-Moreno, Anucha Apisarnthanarak, Bijie Hu, Hakan Leblebicioglu, Yatin Mehta, Toshihiro Mitsuda, and Lul Raka,); and the INICC Advisory Board (Carla J. Alvarado, Nicholas Graves, William R. Jarvis, Patricia Lynch, Dennis Maki, Toshihiro Mitsuda, Cat Murphy, Russell N. Olmsted, Didier Pittet, William Rutala, Syed Sattar, and Wing Hong Seto), who have so generously supported this unique international infection control network.

References

- Rosenthal VD, Guzman S, Orellano PW. Nosocomial infections in medical-surgical intensive care units in Argentina: attributable mortality and length of stay. Am J Infect Control 2003;31:291-5.
- Stevens V, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect 2013;20:0318-24.
- Higuera F, Rangel-Frausto MS, Rosenthal VD, Soto JM, Castanon J, Franco G, et al. Attributable cost and length of stay for patients with central venous catheter-associated bloodstream infection in Mexico City intensive care units: a prospective, matched analysis. Infect Control Hosp Epidemiol 2007;28:31-5.
- Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. Am J Infect Control 2003;31:475-80.
- Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005;33:501-9.
- Rosenthal VD. Central line-associated bloodstream infections in limited-resource countries: a review of the literature. Clin Infect Dis 2009;49:1899-907.
- Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006;145:582-91.
- Rosenthal VD, Maki DG, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, et al. International nosocomial infection control consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008;36:627-37.

- Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. Am J Infect Control 2010;38:95-104.e2.
- Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, et al. International nosocomial infection control consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012;40:396-407.
- Rosenthal VD, Maki DG, Mehta Y, Leblebicioglu H, Memish ZA, Al-Mousa HH, et al. International nosocomial infection control consortium (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. Am J Infect Control 2014;42:942-56.
- Moreno CA, Rosenthal VD, Olarte N, Gomez WV, Sussmann O, Agudelo JG, et al. Device-associated infection rate and mortality in intensive care units of 9 Colombian hospitals: findings of the international nosocomial infection control consortium. Infect Control Hosp Epidemiol 2006;27:349-56.
- Rosenthal VD. Health-care-associated infections in developing countries. Lancet 2011;377:186-8.
- 14. Navoa-Ng JA, Berba R, Rosenthal VD, Villanueva VD, Tolentino MC, Genuino GA, et al. Impact of an international nosocomial infection control consortium multidimensional approach on catheter-associated urinary tract infections in adult intensive care units in the Philippines: international nosocomial infection control consortium (INICC) findings. J Infect Public Health 2013;6:389-99.
- Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32.
- 16. Rosenthal VD, Maki DG, Rodrigues C, Alvarez-Moreno C, Leblebicioglu H, Sobreyra-Oropeza M, et al. Impact of international nosocomial infection control consortium (INICC) strategy on central line-associated bloodstream infection rates in the intensive care units of 15 developing countries. Infect Control Hosp Epidemiol 2010;31:1264-72.
- 17. Rosenthal VD, Ramachandran B, Villamil-Gomez W, Armas-Ruiz A, Navoa-Ng JA, Matta-Cortes L, et al. Impact of a multidimensional infection control strategy on central line-associated bloodstream infection rates in pediatric intensive care units of five developing countries: findings of the international nosocomial infection control consortium (INICC). Infection 2012;40:415-23.
- Rosenthal VD, Duenas L, Sobreyra-Oropeza M, Ammar K, Navoa-Ng JA, de Casares AC, et al. Findings of the international nosocomial infection control consortium (INICC), part III: effectiveness of a multidimensional infection control approach to reduce central line-associated bloodstream infections in the neonatal intensive care units of 4 developing countries. Infect Control Hosp Epidemiol 2013;34:229-37.
- Rosenthal VD, Guzman S, Pezzotto SM, Crnich CJ. Effect of an infection control program using education and performance feedback on rates of intravascular device-associated bloodstream infections in intensive care units in Argentina. Am J Infect Control 2003;31:405-9.
- 20. Higuera F, Rosenthal VD, Duarte P, Ruiz J, Franco G, Safdar N. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico. Crit Care Med 2005;33:2022-7.
- 21. Jaggi N, Rodrigues C, Rosenthal VD, Todi SK, Shah S, Saini N, et al. Impact of an international nosocomial infection control consortium multidimensional approach on central line-associated bloodstream infection rates in adult intensive care units in eight cities in India. Int J Infect Dis 2013;17:e1218-24.
- 22. Leblebicioglu H, Ozturk R, Rosenthal VD, Akan OA, Sirmatel F, Ozdemir D, et al. Impact of a multidimensional infection control approach on central lineassociated bloodstream infections rates in adult intensive care units of 8 cities of Turkey: findings of the international nosocomial infection control consortium (INICC). Ann Clin Microbiol Antimicrob 2013;12:10.
- 23. Rosenthal VD, Udwadia FE, Kumar S, Poojary A, Sankar R, Orellano PW, et al. Clinical impact and cost-effectiveness of split-septum and single-use prefilled flushing device vs 3-way stopcock on central line-associated bloodstream infection rates in India: a randomized clinical trial conducted by the international nosocomial infection control consortium (INICC). Am J Infect Control 2015;43:1040-5.
- McGeer A, Campbell B, Emori TG, Hierholzer WJ, Jackson MM, Nicolle LE, et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991;19:1-7.
- Marschall J, Mermel LA, Classen D, Arias KM, Podgorny K, Anderson DJ, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl):S22-30.
- 26. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51: 1-29.
- Rosenthal VD, Maki DG, Graves N. The international nosocomial infection control consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 2008;36:e1-12.
- Rosenthal VD, Guzman S, Safdar N. Reduction in nosocomial infection with improved hand hygiene in intensive care units of a tertiary care hospital in Argentina. Am J Infect Control 2005;33:392-7.
- 29. Maki DG, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS. Impact of switching from an open to a closed infusion system on rates of central lineassociated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. Infect Control Hosp Epidemiol 2011;32:50-8.

e240

- Rosenthal VD. International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. Am J Infect Control 2016.
- Rosenthal VD. International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. Am J Infect Control 2016;44:e81-90.
- Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, et al. National healthcare safety network report, data summary for 2013, deviceassociated module. Am J Infect Control 2015;43:206-21.
- Geffers C, Gastmeier P. Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System). Dtsch Arztebl Int 2011;108:87-93.
- Villalobos AP, Barrero LI, Rivera SM, Ovalle MV, Valera D. Surveillance of healthcare associated infections, bacterial resistance and antibiotic consumption in high-complexity hospitals in Colombia, 2011. Biomedica 2014;34(Suppl):67-80.
- **35.** Osorio J, Alvarez D, Pacheco R, Gomez CA, Lozano A. Implementation of an insertion bundle for preventing central line-associated bloodstream infections in an intensive care unit in Colombia. Rev Chilena Infectol 2013; 30:465-73.
- **36.** Olarte NM, Valderrama IA, Reyes KR, Garzon MI, Escobar JA, Castro BE, et al. Methicillin-resistant Staphylococcus aureus colonization in a Colombian hospitalintensive care unit: phenotypic and molecular characterization. Biomedica 2011;30:353-61.